1 / 9

Enhancing Treatment Prevalence Data Collection for Drug Addiction Clients

This project aims to gather comprehensive data on drug addiction treatment clients, including long-term cases and profile characteristics. Beginning in 2005, the history of the project outlines its evolution through pilot data collections and revisions. Results from a feasibility assessment in 2007 show reasons for collecting prevalence data and challenges faced by some countries. Resources needed for implementation vary across countries, with an emphasis on human and financial investments. Additional feedback stresses the importance of clear definitions and methodologies, as well as collecting only essential data.

tamira
Download Presentation

Enhancing Treatment Prevalence Data Collection for Drug Addiction Clients

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Treatment Prevalence ProjectBackground information Expert meeting Implementation of the treatment strategy – Module 1: TDI prevalence 24 June 2013

  2. Aim of the project • To have the total number of treatment clients in a country • To collect data on the total number of drug addicts reached by treatment • To get the number of drug users in treatment for long period or more than one year • To have a picture of the profile of the treated population, including its characteristics

  3. History of the project (1) • May 2005: proposal of the Dutch SC member • September 2005: discussion during the TDI expert meeting, NL presentation and setting up a working group • November 2005: proposal for a pilot project presented to NFPs • January 2006: working group meeting 9 volunteer countries and launch of pilot project • Summer 2006: 1st pilot data collection • Sep.-Nov. 2006 presentations first results during the TDI and RTX meeting

  4. History of the project (2) • Summer 2007: 2nd pilot data collection • Summer 2007: feasibility assessment with NFPs • Sep.-Nov.2007: presentations results of 2nd pilot data collection and of the feasibility assessment (TDI and RTX meeting) • 2008: 3rd pilot data collection • 2008 until 2012: TDI revision: TDI prevalence as separated project • 2013: TDI prevalence included in the 2013 Work programme

  5. Results from feasibility assessment (2007) 28 countries replied: 25 MS + TK + HR + NO2 countries not replying: RO, SI Source: Results from a survey to the NFPs on feasibility assessment

  6. Reasons for collecting prevalence data(23 countries) • More complete information on the whole drug problem • Overview of drug treatment population: most part of treatment clients is not included in the current TDI data collection • More “realistic” picture on the number of drug clients • Useful data for treatment planning: it gives information on treatment capacities and treatment needs • Increase research and analysis potentialities with TDI data

  7. Reasons for not collecting prevalence data(5 countries – DK, SP, GR, SW, NO) • Data collection: low feasibility (3 countries) or not feasible (2 countries) • Burden increase in the NFPs and treatment networks • Decrease in data quality • 50% increase in financial (between 20.000 and 300.000 euros) and human resources (between 3 and 5 staff members) in the implementation phase • Less for maintaining the information system • Not much added value to the information currently collected

  8. Resources to be invested • No additional costs for 7 countries • Differences in the remaining countries • Human resources: between 1 and 8 staff • Financial resources: between 20 000 and 100 000 Euros (often including staff cost)

  9. Additional feedback from NFPs and TDI experts • Agreement on implementing data collection on treatment prevalence • Clear definition/methodology needed • Only basic data should be collected

More Related